Department of Orthopaedics, University Clinic Aachen, RWTH Aachen University Clinic, Aachen, Germany.
Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Italy.
Expert Opin Biol Ther. 2021 Mar;21(3):423-430. doi: 10.1080/14712598.2021.1862790. Epub 2020 Dec 30.
: The regenerative capabilities of bone marrow-derived cell therapies (BMCTs) have been employed in combination with core decompression (CD) in the management of osteonecrosis of the femoral head to prevent or delay the necessity of total hip arthroplasty (THA).: The authors conducted a meta-analysis to compare the results of level of evidence I trials comparing CD with and without BMCTs.: Overall, 579 procedures were analyzed: 265 in the CD group and 263 in the CD + BMCTs group. Comparability concerning age and gender, drill size, etiology, and grade of OFNH was found (P > 0.1). At a mean follow up of 82.29 (24 to 360) months, the VAS scored favourably for the CD + BMCTs group (mean difference: -12.88; P < 0.0001), as well the rate of THA (odd ratio: -0.14; P < 0.0001). Time to failure (P = 0.4) and to THA (P = 0.9) was similar between the two groups, as was the rate of failure (P = 0.3).: In patients with femoral head osteonecrosis, core decompression combined with BMCTs demonstrated reduced pain and lower rate of total hip arthroplasty compared to core decompression as an isolated procedure.
骨髓来源细胞疗法 (BMCT) 的再生能力已与核心减压术 (CD) 联合应用于股骨头坏死的治疗中，以预防或延迟全髋关节置换术 (THA) 的需要。作者进行了一项荟萃分析，以比较比较 CD 联合和不联合 BMCT 的 I 级证据试验的结果。总体上，分析了 579 例手术：CD 组 265 例，CD+BMCTs 组 263 例。发现年龄和性别、钻头大小、病因和 OFNH 分级方面具有可比性 (P>0.1)。在平均 82.29 个月（24 至 360）的随访中，CD+BMCTs 组的 VAS 评分更为有利（平均差异：-12.88；P<0.0001），THA 率也更低（优势比：-0.14；P<0.0001）。两组之间的失败时间（P=0.4）和 THA 时间（P=0.9）相似，失败率也相似（P=0.3）。在股骨头坏死患者中，与单独的核心减压术相比，核心减压术联合 BMCTs 可减轻疼痛，降低全髋关节置换术的发生率。
